Based on market data through Nov 12, 2026, StockInvest.us rates Recursion Pharmaceuticals, Inc. (RXRX) as a Sell Candidate with a technical score of -2.01 on its -10 to +10 scale. The rating is ...

Instant and sorcery recursion is the ability to bring back instants and sorceries from your graveyard so you can use them again. Normally, once you cast these spells, they go straight to the graveyard ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

RXRX is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.26 since the market last closed. This is a 7.24% ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Flint launched on October 21, 2026. It is a 40-billion-parameter model built specifically for coding work. On a MacBook Pro with an M4 Pro chip, Flint generates over 125 tokens per second. On RTX ...

On February 5, 2026, OpenAI introduced GPT-5.3-Codex and wrote in its release notes that early versions of the model were “instrumental in creating itself,” helping to debug training runs, manage ...

For the past few days I’ve been testing an impressive open-weight AI coding model called Flint. It suggests that fully recursive self-improvement, or RSI—an exciting and controversial approach that ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

What happens when artificial intelligence systems start to think for themselves, make themselves more powerful and escape human control in their quest to achieve superintelligence? That prospect has ...